Sign inJoin waitlistJoin the waitlist

Carla Nester

Fellowship Director, Division of Nephrology, Dialysis and Transplantation · Roy J. and Lucille A. Carver College of Medicine

Credentials: · · · · · · · · ·

History

Nephrology, Dialysis and Transplantation Fellowship · Roy J. and Lucille A. Carver College of Medicine
Present
Roy J. and Lucille A. Carver College of Medicine
Present
Roy J. and Lucille A. Carver College of Medicine
Present

Nephrology
University of North Carolina Hospitals
2010–2012
Pediatric Nephrology
University of North Carolina Hospitals
2007–2010
Pediatrics
University of North Carolina Hospitals
2004–2007
Central Michigan University College of Medicine/CMU Medical Education Partners
2001–2004
Internal Medicine
University of North Carolina Hospitals
1998–2001
Penn State College of Medicine
1994–1998

Research

Syndromes of thrombotic microangiopathy
Review · New England Journal of Medicine · 2014 · 887 citations
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Kidney International · 2021 · 757 citations
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
Kidney International · 2017 · 549 citations

Richard Smith
40 papers
Christie Thomas
10 papers
Andrew Bomback
9 papers
HT
Howard Trachtman
8 papers
Sanjeev Sethi
8 papers
John Sperati
7 papers
Bradley Dixon
6 papers
Dana Rizk
6 papers
Fernando Fervenza
6 papers
Gerald Appel
6 papers
Katherine Twombley
6 papers
James George
5 papers

Grants

C3 Glomerulopathy -- A Collaborative Study
National Institute of Diabetes and Digestive and Kidney Diseases · R01
PI · $5.6M · University of Iowa
2017–2027

Clinical trials

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Principal investigator · Terminated · Phase 2
BioCryst Pharmaceuticals
2022
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Principal investigator · Terminated · Phase 1
Celldex Therapeutics
2013–2014
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2021–2027
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2019–2036